Latest Insider Transactions at Aprea Therapeutics, Inc. (APRE)
This section provides a real-time view of insider transactions for Aprea Therapeutics, Inc. (APRE). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Aprea Therapeutics, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Aprea Therapeutics, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 03
2022
|
Gregory Alan Korbel SVP, Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
8,390
-28.11%
|
$0
$0.8 P/Share
|
|
Jun 03
2022
|
Scott M Coiante SVP, Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
35,284
-29.51%
|
$0
$0.8 P/Share
|
|
Jun 03
2022
|
Christian S Schade Director |
SELL
Payment of exercise price or tax liability
|
Direct |
65,770
-22.48%
|
$0
$0.8 P/Share
|
|
May 18
2022
|
Christian S Schade Director |
BUY
Open market or private purchase
|
Direct |
37,500
+11.36%
|
$0
$0.64 P/Share
|
|
May 18
2022
|
Bernd R. Seizinger Director |
BUY
Open market or private purchase
|
Direct |
50,000
+13.57%
|
$0
$0.71 P/Share
|
|
Mar 10
2022
|
Lars B. Abrahmsen SVP, Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
24,700
+36.11%
|
-
|
|
Mar 10
2022
|
Eyal C. Attar SVP, Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
42,900
+32.3%
|
-
|
|
Mar 10
2022
|
Scott M Coiante SVP, Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
42,900
+26.41%
|
-
|
|
Mar 10
2022
|
Gregory Alan Korbel SVP, Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,989
-6.25%
|
$1,989
$1.82 P/Share
|
|
Mar 10
2022
|
Gregory Alan Korbel SVP, Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
16,000
+33.44%
|
-
|
|
Mar 10
2022
|
Christian S Schade Director |
BUY
Grant, award, or other acquisition
|
Direct |
100,100
+28.18%
|
-
|
|
Feb 28
2022
|
Eyal C. Attar SVP, Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
36,000
-43.37%
|
$36,000
$1.73 P/Share
|
|
Feb 25
2022
|
Scott M Coiante SVP, Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
14,817
-16.2%
|
$14,817
$1.74 P/Share
|
|
Feb 25
2022
|
Gregory Alan Korbel SVP, Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,326
-7.72%
|
$1,326
$1.74 P/Share
|
|
Feb 25
2022
|
Christian S Schade Director |
SELL
Payment of exercise price or tax liability
|
Direct |
21,644
-12.25%
|
$21,644
$1.74 P/Share
|
|
Dec 01
2021
|
Gregory Alan Korbel SVP, Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
27,500
-61.57%
|
$82,500
$3.96 P/Share
|
|
Dec 01
2021
|
Gregory Alan Korbel SVP, Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
27,500
+38.11%
|
$0
$0.92 P/Share
|
|
Nov 01
2021
|
Gregory Alan Korbel SVP, Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
27,500
-61.57%
|
$137,500
$5.0 P/Share
|
|
Nov 01
2021
|
Gregory Alan Korbel SVP, Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
27,500
+38.11%
|
$0
$0.92 P/Share
|
|
Oct 01
2021
|
Gregory Alan Korbel SVP, Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
27,500
-61.57%
|
$110,000
$4.89 P/Share
|
|
Oct 01
2021
|
Gregory Alan Korbel SVP, Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
27,500
+38.11%
|
$0
$0.92 P/Share
|
|
Oct 01
2021
|
Lars B. Abrahmsen SVP, Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
50,000
-72.46%
|
$200,000
$4.89 P/Share
|
|
Oct 01
2021
|
Lars B. Abrahmsen SVP, Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
50,000
+42.02%
|
$0
$0.92 P/Share
|
|
Sep 20
2021
|
Lars B. Abrahmsen SVP, Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
25,000
-56.82%
|
$100,000
$4.97 P/Share
|
|
Sep 20
2021
|
Lars B. Abrahmsen SVP, Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
25,000
+36.23%
|
$0
$0.92 P/Share
|
|
Sep 20
2021
|
Gregory Alan Korbel SVP, Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
32,960
-42.85%
|
$131,840
$4.98 P/Share
|
|
Sep 20
2021
|
Gregory Alan Korbel SVP, Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
27,500
+38.11%
|
$0
$0.92 P/Share
|
|
Sep 16
2021
|
Eyal C. Attar SVP, Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
15,968
-16.13%
|
$63,872
$4.68 P/Share
|
|
Sep 10
2021
|
Gregory Alan Korbel SVP, Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,724
-7.08%
|
$6,896
$4.59 P/Share
|
|
Aug 25
2021
|
Eyal C. Attar SVP, Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
9,032
-8.36%
|
$27,096
$3.98 P/Share
|
|
Aug 25
2021
|
Scott M Coiante SVP, Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
7,534
-7.61%
|
$22,602
$3.98 P/Share
|
|
Aug 25
2021
|
Gregory Alan Korbel SVP, Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,149
-4.51%
|
$3,447
$3.98 P/Share
|
|
Jun 30
2021
|
Fouad Namouni Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,610
+50.0%
|
-
|
|
Jun 30
2021
|
Bernd R. Seizinger Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,610
+1.69%
|
-
|
|
Jun 30
2021
|
Richard Peters Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,610
+50.0%
|
-
|
|
Jun 30
2021
|
Michael Aaron Kelly Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,610
+50.0%
|
-
|
|
Jun 30
2021
|
John B Henneman Iii Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,610
+32.42%
|
-
|
|
Mar 10
2021
|
Gregory Alan Korbel SVP, Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
15,000
+37.04%
|
-
|
|
Feb 25
2021
|
Gregory Alan Korbel SVP, Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
10,000
+48.78%
|
-
|
|
Feb 25
2021
|
Scott M Coiante SVP, Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
96,500
+43.63%
|
-
|
|
Feb 25
2021
|
Christian S Schade Director |
BUY
Grant, award, or other acquisition
|
Direct |
165,500
+41.66%
|
-
|
|
Feb 25
2021
|
Lars B. Abrahmsen SVP, Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
19,000
+50.0%
|
-
|
|
Feb 25
2021
|
Gregory S. Wessels SVP, Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
16,000
+50.0%
|
-
|
|
Feb 25
2021
|
Eyal C. Attar SVP, Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
108,000
+45.49%
|
-
|
|
Dec 28
2020
|
Redmile Group, LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
500,000
-11.06%
|
$2,500,000
$5.69 P/Share
|
|
Oct 05
2020
|
5 Am Ventures Iv, L.P. |
SELL
Open market or private sale
|
Indirect |
175,000
-55.82%
|
$4,375,000
$25.3 P/Share
|
|
Oct 07
2019
|
Redmile Group, LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
400,000
+14.99%
|
$6,000,000
$15.0 P/Share
|
|
Oct 07
2019
|
Redmile Group, LLC > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
1,868,718
+50.0%
|
-
|